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Silencing Dkk1 expression rescues
dexamethasone-induced suppression of primary
human osteoblast differentiation
Joseph S Butler1,2*, Joseph M Queally1,2, Brian M Devitt1,2, David W Murray1, Peter P Doran1, John M O’Byrne2
Abstract
Background: The Wnt/b-catenin pathway is a major signaling cascade in bone biology, playing a key role in bone
development and remodeling. The objectives of this study were firstly, to determine the effects of dexamethasone
exposure on Wnt/b-catenin signaling at an intracellular and transcriptional level, and secondly, to assess the
phenotypic effects of silencing the Wnt antagonist, Dickkopf-1 (Dkk1) in the setting of dexamethasone exposure.
Methods: Primary human osteoblasts were exposed in vitro to 10-8 M dexamethasone over a 72 h time course.
The phenotypic marker of osteoblast differentiation was analyzed was alkaline phosphatase activity. Intracellular
b-catenin trafficking was assessed using immunoflourescence staining and TCF/LEF mediated transcription was
analyzed using a Wnt luciferase reporter assay. Dkk1 expression was silenced using small interfering RNA (siRNA).
Results: Primary human osteoblasts exposed to dexamethasone displayed a significant reductions in alkaline
phosphatase activity over a 72 h time course. Immunoflourescence analaysis of b-catenin localization demonstrated
a significant reduction in intracytosolic and intranuclear b-catenin in response to dexamethasone exposure. These
changes were associated with a reduction of TCF/LEF mediated transcription. Silencing Dkk1 expression in primary
human osteoblasts exposed to dexamethasone resulted in an increase in alkaline phosphatase activity when
compared to scrambled control.
Conclusions: Wnt/b-catenin signaling plays a key role in regulating glucocorticoid-induced osteoporosis in vitro.
Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast
differentiation. Targeting of the Wnt/b-catenin signaling pathway offers an exciting opportunity to develop novel
anabolic bone agents to treat osteoporosis and disorders of bone mass.
Background
Osteoporosis is a systemic skeletal disorder characterized
by low bone mass and a progressive micro-architectural
deterioration of bone tissue, leading to an increase in
bone fragility and ultimately susceptibility to fracture [1].
There has been an increasing interest in elucidating
the role played by developmental pathways, such as Wnt/
b-catenin cascade, in bone mass regulation [2].
Wnt proteins are a family of secreted cysteine-rich
glycoproteins with functions relating to cell specifica-
tion, formation of the body plan, cell growth, prolifera-
tion, differentiation and apoptosis [3-5]. Wnts are
defined by their sequence homology to Drosophila wing-
less and the murine int-1 proto-oncogene. Human and
mouse genomes have been shown to encode 19 and
18 Wnt genes, respectively [6]. Wnt proteins activate a
number of distinct intracellular signal transduction
pathways which have been implicated in numerous
developmental and disease processes.
The role of canonical Wnt signaling in bone develop-
ment and remodeling was first identified when the loss-
of-function mutation of the LDL receptor-related
protein (LRP5) was associated with osteoporosis psuedo-
glioma syndrome, a recessive disorder characterized by
osteogenesis imperfecta with low bone mass and a pre-
disposition to fractures as well as ocular defects [7,8].
Subsequently, gain-of-function mutations of the LRP5
have been shown to be associated with disorders of
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increased bone mass, such as Van Buchem’s disease,
osteopetrosis, and endosteal hyperostosis [9-11].
In this study, we focused our attention on the role
played by Wnt/b-catenin signaling in glucocorticoid-
induced osteoporosis. We determined the effects of
dexamethasone exposure on Wnt/b-catenin signaling in
primary human osteoblasts. We also examined the phe-
notypic effects of attenuating the expression of Dkk1, a
Wnt antagonist, in primary human osteoblasts exposed
to dexamethasone.
Methods
Cell Culture
Primary human osteoblasts from normal human hip
samples were (Promocell, Heidelberg, Germany). Cells
were cultured in Osteoblast Growth Medium (Promo-
cell, Heidelberg, Germany) containing 10% FCS and
antibiotics (100 IU/ml penicillin and 100 μg/ml strepto-
mycin) at 37°C, 5% CO2. For all experiments primary
human osteoblasts used were between 2th and 5th pas-
sage. Cells were treated over a 48 h time course with
10-8 M Dexamethasone (Dex) (Sigma-Aldrich, Poole,
UK). Institutional Review Board approval for this study
was obtained from the Mater Misericordiae University
Hospital Research Ethics Committee.
Alkaline Phosphatase Activity
Alkaline phosphatase (ALP) activity was assayed by the
measurement of released p-nitrophenol from p-nitro-
phenolphosphate (pNPP). Post-treatment cell lysates
were collected by Cell Lytic MT (Sigma-Aldrich, Poole,
UK) treatment and the extracted protein was frozen at
-80°C for at least 2 h prior to ALP activity assay to dis-
rupt cellular membranes. 10 μl of thawed cell lysates
were incubated with 200 μl pNPP reagent (Sigma-
Aldrich, Poole, UK) for 30 min at room temperature.
ALP activity was measured at 405 nm and normalized
to total protein extracted, which was measured using a
bicinchoninic acid (BCA) protein assay kit (Pierce,
Rochford, Illinois). One unit of ALP activity was defined
as the amount required for the liberation of 1.0 μmol
p-nitrophenol/min/mg of cellular protein.
Immunoflourescence Staining
Beta-catenin was visualized by indirect immunocyto-
chemistry using a mouse anti b-catenin (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) as the primary
antibody. Primary human osteoblasts were plated on
coverslips and treated with Dex-containing media. Cells
were fixed in ice-cold methanol and permeabilized for
ten minutes. Cells were then blocked with 10% goat
serum for ten minutes at room temperature. Samples
were incubated for 1 hr with primary antibody followed
by a 30 min incubation with a goat anti-mouse TRITC-
conjugate. Cells were viewed with a Zeiss Axioskop 40
fluorescence microscope using 20× objectives. Digital
images were captured with a ProgRes C10plus research
digital camera (Jenoptik Laser Optik Systeme GmbH,
Jena, Germany). The digital images were processed
using the ProgRes CapturePro 2.1 image analysis soft-
wear package (Jenoptik Laser Optik Systeme GmbH,
Jena, Germany).
Generation of Conditioned Media
Mouse Wnt3a overexpressing cells (L-Wnt3a) and con-
trol non-transfected L-cells were obtained from the
American Type Culture Collection (ATCC, Manassas,
USA) and cultured in DMEM with glutamax, 10% FBS,
100 IU/ml penicillin and 100 μg/ml streptomycin.
L-Wnt3a culture medium was supplemented with
400 μg/ml geneticin to maintain selective pressure. Con-
ditioned medium from L-Wnt3a and control L-cells was
collected according to the manufacturer’s instructions.
Briefly, cells were passaged 1:10 in 8 ml medium with-
out geneticin and left to grow for 10 days. Medium was
collected from each cell line and replaced with 8 ml
fresh medium for a further 3 days. This second batch of
medium was then collected and the cells discarded. First
and second batches were combined, sterile filtered
(0.2 μm) and stored at -20°C until required.
b-Catenin/TCF Transcription Reporter Assay
Primary human osteoblasts plated in 24-well plates at
2 × 104/cm2 were transiently transfected with the Wnt-
luciferase reporter construct pBAR (1 μg total; Dr. RT.
Moon, University of Washington, Seattle, WA, USA)
and the control reporter pfuBAR (1 μg total; Dr. RT.
Moon, University of Washington, Seattle, WA, USA)
using GeneJuice (Novagen, Madison, WI, USA). The
b-catenin activated reporter (pBAR) contains 12 TCF
binding sites (5’-AGATCAAAGG-3’) separated by
distinct 5 base linkers. These elements are directly
upstream of a minimal thymidine kinase promoter
which then drives the expression of firefly luciferase.
The control reporter pfuBAR is identical to its sister
reporter with the exception of a two base substitution
in each TCF binding site. Both reporters contain a sepa-
rate PGK promoter that constitutively drives the expres-
sion of a puromycin resistance gene, and both are in a
lentiviral platform. Co-transfection with 0.5 μg of the
internal control reporter pSL9EF1a(P)RLUC (Dr. RT.
Moon, University of Washington, Seattle, WA, USA),
driving constitutive expression of Renilla luciferase, was
systematically performed to normalize for transfection
efficiency. Sixteen hours after transfection, cells
were washed and cultured for 48 hr in Dex-containing
media with 2% FCS, in the presence or absence Wnt3a-
conditioned media. Cells were lysated, and luciferase
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assays were performed with the Dual Luciferase Assay
Kit (Promega, Madison, WI, USA) according to manu-
facturer’s instructions. 10 μl of cell lysates were first
assayed for firefly luciferase and then Renilla luciferase
activity. Firefly luciferase activity was normalized to
Renilla luciferase activity.
siRNA-mediated Dkk1 Gene Silencing
Predesigned short interfering RNA (siRNA) targeting
human Dkk1 (Hs_DKK1_1) and a control scrambled
RNA targeting a sequence not sharing homology with
the human genome (AllStars Negative Control) were
purchased (Qiagen, Crawley, UK). Primary human
osteoblasts were transfected with siRNAs and control
scrambled RNA using the RNAiFect transfection reagent
(Qiagen, Crawley, UK) as per manufacturer’s protocol.
Briefly, siRNA or scrambled RNA solutions were pre-
pared 15-25 min before the cell transfection. The ratio
of siRNA to the RNAiFect reagent was 1 μg siRNA to
3 μl transfection reagent. The siRNA-RNAiFect transfec-
tion complexes were incubated for 15 min at room tem-
perature (15-25°C). Osteoblast growth medium was
replaced with fresh medium and the siRNA-RNAiFect
suspension was added drop-wise onto the cells. The
cells with adherent complexes were incubated for 24 h
at 37°C, 5% CO2, at which point the medium was chan-
ged and experimentation was commenced. Transfection
efficiency was determined in three preliminary experi-
ments in which a fluorescent control RNA-RNAiFect
complex (Qiagen, Crawley, UK) was transfected into the
cells instead of the siRNA-RNAiFect complex. The
uptake of the fluorescent RNA as determined by fluores-
cence microscopy was in the range of 75-85%. The ratio
of siRNA to the RNAiFect reagent was determined three
preliminary experiments with a ratio of 1 μg siRNA:3 μl
RNAiFect providing a maximal gene silencing of 75%
knockdown as determined by qRT-PCR.
Quantitative Real Time PCR
Dkk-1 mRNA regulation in primary human osteoblasts
treated with dexamethasone was measured by quantita-
tive Real Time PCR using human Dkk-1 QuantiTect
assay (Qiagen, Crawley, UK). The QuantiProbe sequence
for Dkk-1 was 5’-CACACCAAAGGACAAGA-3’. The
forward primer sequence for Dkk-1 was 5’-GGGAAT-
TACTGCAAAAATGGAATA-3’, and the reverse primer
sequence was 5’-ATGACCGGAGACAAACAGAAC-3’.
Total RNA was extracted by TRI-reagent/chlorophorm
method, then assayed in duplicate using a Rotorgene 3.0
Real Time PCR instrument (Corbett Research, Cam-
bridge, UK) and the Real Time PCR amplification kit
SYBR Green I (Qiagen, Crawley, UK). Using gene speci-
fic primer pairs, Dkk1 gene products were measured by
Absolute Quantification and were reported as a function
of crossing time (Ct), the cycle number at which PCR
amplification becomes linear. mRNA expression was
normalized to control and GAPDH expression resulting
in Mean Fold Change values or ΔΔCt. Following cycling,
to ensure specificity, melt curve analysis was carried out
to verify the amplification of PCR products starting
at 65°C and ramping to 95°C at 0.1°C/sec. One peak in
the melt curve indicated no secondary, non-specific
products were formed.
Dkk1 ELISA
Human Dkk1 ELISA kit (R&D Systems Europe Ltd,
Abingdon, UK) was obtained to analyse Dkk1 protein
expression on cell supernatant. ELISA was performed in
accordance with manufacturer’s protocols.
Statistical Analysis
All experimental data presented were obtained from
three independent experiments, each in triplicate. Data
were expressed as mean ± SE. Statistical differences
were calculated using Student’s t-test or ANOVA for
multiple comparisons. p values < 0.05 was considered
statistically significant.
Results
Dexamethasone exposure in vitro reduces alkaline
phosphatase activity deposition in primary human
osteoblasts
To study the effects of dexamethasone, on markers of
osteoblast differentiation, we exposed primary human
osteoblasts to 10-8 M dexamethasone over a 72 h time
course. The marker of osteoblast differentiation assessed
was alkaline phosphatase activity.
Primary human osteoblasts exposed to dexamethasone
in vitro displayed a reduction in alkaline phosphatase
activity over a 72 h time course (Figure 1). Significant
reductions in alkaline phosphatase activity were seen at
12 h (p < 0.001), 24 h (p < 0.001), 48 (p < 0.001), 72 h
(p < 0.001; Student’s t-test) of dexamethasone exposure
when compared to control primary human osteoblasts
(Figure 1).
Dexamethasone-induced inhibition of bone turnover in
vitro is driven by a Wnt-dependant mechanism
In order to determine the effects of dexamethasone
exposure on Wnt/b-catenin signaling in primary human
osteoblasts, we firstly examined b-catenin trafficking
using immunoflourescence analysis. Primary human
osteoblasts were grown to confluency and exposed to
10-8 M dexamethasone over a 48 h time course.
Control primary human osteoblasts, not exposed to
dexamethasone treatment and cultured in osteoblast
growth medium alone, demonstrated a strong perinuc-
lear and intranuclear staining of b-catenin, representing
Butler et al. BMC Musculoskeletal Disorders 2010, 11:210
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activated Wnt/b-catenin signaling (Figure 2a). Primary
human osteoblasts exposed to dexamethasone demon-
strated a reduction in intracellular staining for b-catenin
at 24 h (Figure 2b) and this reduction in b-catenin
staining persisted at 48 h (Figure 2c), representing a sig-
nificant inhibition of Wnt/b-catenin signaling.
Since significant changes in intracellular b-catenin traf-
ficking were observed, experiments were performed to
elucidate the effects of dexamethasone exposure on Wnt/
b-catenin signaling at a transcriptional level. We transi-
ently transfected primary human osteoblasts with the
highly sensitive Wnt-luciferase reporter construct pBAR
and the control reporter pfuBAR, and exposed them to
10-8 M dexamethasone over a 48 h time course. Signifi-
cant reductions in luciferase activity were identified at
24 h (p < 0.01) and 48 h (p < 0.01; Student’s t-test) of
dexamethasone treatment in the pBAR reporter cells,
and the luciferase activity in the pfuBAR reporter cells
remained unchanged during treatment (Figure 3).
In order to validate these findings primary human
osteoblasts transfected with pBAR were treated with
Wnt 3a conditioned media (Wnt agonist) and L-cell
conditioned media (control) over a 48 h time course.
Significant reductions in luciferase activity were identi-
fied when 10-8 M dexamethasone was added to both
Wnt 3a conditioned media (p < 0.001) and control
L-cell conditioned media (p < 0.05; Student’s t-test) over
the 48 h time course, representing a reduction in Wnt/
b-catenin signaling through the inhibition of TCF/LEF
mediated transcription (Figure 4).
Silencing of Dkk1 expression rescues dexamethasone-
induced inhibition of osteoblast differentiation, increasing
alkaline phosphatase activity and calcium deposition in
primary human osteoblasts
In order to explore the phenotypic effects that aberra-
tions in Wnt/b-catenin signaling have on primary
human osteoblasts exposed to dexamethasone, we
silenced the expression of Dickkopf-1 (Dkk1), a power-
ful Wnt antagonist, using siRNA. Primary human osteo-
blasts were transfected with siRNA targeting Dkk1
expression or scrambled control RNA and Dkk1 gene
expression was assessed using quantitative RT-PCR
(Figure 5) and ELISA (Figure 6) to confirm knockdown.
Quantitative RT-PCR confirmed a 75% reduction in
Dkk1 gene expression in the siRNA transfected cells
relative to untransfected control cells. This represented
a significant reduction when compared to both the
scrambled control and transfection control cells (ie. cells
treated with RNAiFect alone), which demonstrated no
change in Dkk1 gene expression. This reduction in
Dkk1 expression was confirmed at protein level when
the Dkk1 concentration of cell supernatant was analysed
using ELISA. An 85% reduction in Dkk1 concentration
was seen in the cell supernatant of siRNA transfected
cells relative to untransfected control cells. This also
represented a significant reduction when compared to
both scrambled control and transfection control cells.
In order to confirm that knockdown of Dkk1 was
inhibiting Wnt/b-catenin signaling in primary human
osteoblasts, we firstly examined b-catenin trafficking
Figure 1 Primary human osteoblasts exposed to dexamethasone in vitro displaying a reduction in alkaline phosphatase activity over
a 72 h time course. Significant reductions in alkaline phosphatase activity and calcium deposition identified at 12 h, 24 h, 48 h and 72 h of
dexamethasone exposure when compared to control primary human osteoblasts. ***p < 0.001 versus control.
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using immunoflourescence analysis. Primary human
osteoblasts were grown to confluency and transfected
with siRNA targeting Dkk1 expression or scrambled
control RNA. siRNA transfected primary human osteo-
blasts (Figure 7a) demonstrated a strong perinuclear
and intranuclear staining of b-catenin, in comparison
to scrambled control primary human osteoblasts
(Figure 7b). This represents activation of Wnt/b-
catenin signaling in response to silencing Dkk1
expression.
These changes in intracellular b-catenin trafficking
were accompanied by changes in Wnt/b-catenin signal-
ing at a transcriptional level. Primary human osteoblasts
transfected with Wnt-luciferase reporter construct
pBAR and the control reporter pfuBAR, were subse-
quently treated with siRNA targeting Dkk1 expression
or scrambled control RNA. A significant increase in
luciferase activity was observed in the siRNA transfected
cells when compared to scrambled control cells
(p < 0.001; Student’s t-test) in the pBAR reporter cells,
whilst the luciferase activity in the pfuBAR reporter cells
remained unchanged during treatment (Figure 8).
Primary human osteoblasts transfected with siRNA
targeting Dkk1 expression or scrambled control RNA
were subsequently exposed to 10-8 M dexamethasone
over a 72 h time course. Bone turnover was assessed by
analyzing alkaline phosphatase activity. Control primary
human osteoblasts exposed to dexamethasone over the
72 h time course displayed reductions in alkaline phos-
phatase activity at 12 h, 24 h, 48 h and 72 h. However,
when primary human osteoblasts were transfected with
siRNA attenuating Dkk1 expression, there was an
increase in alkaline phosphatase activity at each indivi-
dual time point when compared to scrambled control.
Significant increases relative to scrambled control were
identified at 12 h (p < 0.05), 24 h (p < 0.05), 48 h
(p < 0.01) and 72 h (p < 0.01; Student’s t-test) of dexa-
methasone exposure (Figure 9).
Discussion
Osteoporosis is a skeletal disorder characterized by low
bone mass and progressive micro-architectural dete-
rioration of bone tissue with a consequent increase in
bone fragility and propensity to fracture. Reduced bone
mass is a result of an imbalance between the tightly
regulated processes of bone formation and bone resorp-
tion, controlled by osteoblasts and osteoclasts respec-
tively. There have been many cell signaling cascades
linked to bone mass regulation. One pathway seen as
critical for bone mass accrual, bone remodeling and
even fracture repair is the Wnt/b-catenin pathway.
The Wnt/b-catenin pathway plays an important role
in the development and maintenance of many tissues
and organs, with disturbances in Wnt signaling
Figure 2 Immunoflourescence microscopy demonstrating b-
catenin expression in primary human osteoblasts exposed to
10-8 M dexamethasone over a 48 h time course. b-catenin
stained with anti-b-catenin antibody demonstrating its perinuclear
and intranuclear localization in control cells (a) and a significant
reductions in intracellular localization at 24 h (b) and 48 h (c) after
treatment.
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implicated in multiple disease processes [5,12]. Recent
evidence has implicated the Wnt b-catenin pathway as a
major signaling cascades in bone biology [13-17].
Human genetic studies have revealed a critical role of
the Wnt/b-catenin pathway in bone mass acquisition
and maintenance [18]. Loss of function of the Wnt co-
receptor, LRP5, have been shown to lead to disorders of
decreased bone mass, such as Osteoporosis Pseudo-
glioma Syndrome (OPS) [7]. Whereas, gain of function
mutations of LRP5 have been shown to lead to disorders
Figure 3 A reduction in b-catenin expression during dexamethasone treatment results in a reduction in Wnt/b-catenin signaling
through TCF/LEF mediated transcription. Primary human osteoblasts were transiently transfected with pBAR (wild type promoter) and pfuBAR
(mutant promoter), and exposed them to 10-8 M dexamethasone over a 48 h time course. Significant reductions in luciferase activity were
identified at 24 h and 48 h after treatment in the pBAR cells, whilst luciferase activity in the pfuBAR cells remained unchanged. **p < 0.01,
***p < 0.001 versus pfuBAR.
Figure 4 In order to validate these findings, cells transfected with pBAR were treated with Wnt 3a conditioned media (Wnt agonist)
and L-cell conditioned media (control). Significant reductions in luciferase activity were identified when 10-8 M dexamethasone was added to
both conditioned media over a 48 hr time course. *p < 0.05, ***p < 0.001 versus control.
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of increased bone mass such as sclerostosis [19], Van
Buchem’s disease [20], osteopetrosis [9] and endosteal
hyperostosis [10].
The Dkk family of extracellular proteins consists of
four members (Dkk1, Dkk2, Dkk3 and Dkk4). Dkk1
and Dkk2 are the best characterized members of this
family. Dkk1 has been shown to inhibit canonical
Wnt/b-catenin signaling pathway in several different
organisms and cell types [21-25]. The involvement of
Dkk2 in regulating bone development was recently
demonstrated when it was shown that knockout mice
lacking Dkk2 developed osteopenia [26]. Initially
increased Dkk1 expression was found to be associated
with the lytic bone lesions in patients with multiple
Figure 5 Primary human osteoblasts transfected with siRNA targeting Dkk1 expression or scrambled control RNA. Dkk1 gene
expression assessed using quantitative RT-PCR to confirm knockdown. **p < 0.01, ***p < 0.001 versus transfection control and scrambled control.
Figure 6 Primary human osteoblasts transfected with siRNA targeting Dkk1 expression or scrambled control RNA. Dkk1 protein
expression assessed using ELISA to confirm knockdown. **p < 0.01, ***p < 0.001 versus transfection control and scrambled control.
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myeloma, suggesting that Dkk1 might inhibit osteo-
blast differentiation or function [27]. This has been
subsequently been reinforced by data showing Dkk1 to
be a powerful negative regulator of osteoblast function
in vitro and in vivo and that a decrease in its expres-
sion is sufficient to induce a strong anabolic response
in the skeleton [28-30].
Our data emphasizes the key role of Wnt/b-catenin
signaling in regulating bone development and remodel-
ing, further strengthening its crucial role in glucocorti-
coid-induced osteoporosis [31-33]. Primary human
osteoblasts exposed to dexamethasone in vitro display a
reduction in alkaline phosphatase activity over a 72 h
time course when compared to control osteoblasts.
Figure 7 Immunoflourescence microscopy demonstrating b-catenin expression in primary human osteoblasts transfected with
scrambled control RNA (a) or siRNA targeting Dkk1 expression (b). siRNA transfected primary human osteoblasts demonstrated a strong
perinuclear and intranuclear staining of b-catenin, in comparison to scrambled control primary human osteoblasts. This represents activation of
Wnt/b-catenin signaling in response to silencing Dkk1 expression.
Figure 8 This increase in b-catenin expression by silencing Dkk1 expression results in an increase in Wnt/b-catenin signaling through
TCF/LEF mediated transcription. Primary human osteoblasts were transiently transfected with pBAR (wild type promoter) and pfuBAR (mutant
promoter), and subsequently treated with siRNA targeting Dkk1 expression or scrambled control RNA. A significant increase in luciferase activity
was observed in the siRNA transfected cells when compared to scrambled control cells in the pBAR reporter cells, whilst luciferase activity in the
pfuBAR cells remained unchanged (c). ***p < 0.001 versus scrambled control.
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These phenotypic changes are driven by a Wnt/b-cate-
nin-dependent mechanism as clearly demonstrated by
both alterations in b-catenin trafficking and changes in
TCF/LEF-mediated transcription.
Dkk1 is a powerful antagonist of canonical Wnt/
b-catenin signaling. Silencing Dkk1 expression rescues
dexamethasone-induced suppression of primary human
osteoblast function. Increased alkaline phosphatase
activity was displayed by primary human osteoblasts
treated with siRNA targeting Dkk1 expression when
compared to scrambled control cells over a 72 h time
course of dexamethasone exposure. The pharmacologi-
cal targeting of the Wnt/b-catenin signaling pathway
offers an exciting opportunity for the development of
novel anabolic bone agents to treat osteoporosis and
disorders of bone mass.
Conclusion
Wnt/b-catenin signaling plays a key role in regulating
glucocorticoid-induced osteoporosis in vitro. Silencing
Dkk1 expression rescues dexamethasone-induced sup-
pression of primary human osteoblast differentiation.
Targeting of the Wnt/b-catenin signaling pathway offers
an exciting opportunity to develop novel anabolic bone
agents to treat osteoporosis and disorders of bone mass.
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